FDA approves Roche's Tecentriq in combination with chemotherapy for the initial treatment of adults with extensive-stage small cell lung cancer
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) treatment of adults with extensive-stage small cell lung cancer (ES-SCLC).
Merck to collaborate with GenScript to accelerate cell and gene therapy industrialization in China
- Details
- Category: Merck Group
Merck, a leading science and technology company, today announced the signing of a non-binding Memorandum of Understanding with Chinese biotech company GenScript for a strategic alliance focusing on plasmid and viral vector manufacturing.
US FDA grants saracatinib Orphan Drug Designation for idiopathic pulmonary fibrosis
- Details
- Category: AstraZeneca
The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for saracatinib, a potential new medicine for the treatment of idiopathic pulmonary fibrosis (IPF), a type of lung disease that results in scarring (fibrosis) of the lungs. Saracatinib is an inhibitor of src kinase which regulates broad cell functions including cell growth and cell differentiation.
Novartis joins the Global Chagas Disease Coalition and also announces first multinational, prospective, randomized study in people with chronic Chagas cardiomyopathy
- Details
- Category: Novartis
At the Annual Meeting of the Global Chagas Disease Coalition in Barcelona, Spain, Novartis announced that it is joining the Coalition as a member contributor. In addition, the company announced its commitment to launch a multinational, prospective, randomized study with heart failure drug, Entresto® (sacubitril / valsartan), in people with chronic Chagas cardiomyopathy, one form of heart failure with reduced ejection fraction.
Merck announces collaboration with Iktos for generative artificial intelligence (AI) technology
- Details
- Category: Merck Group
Merck, a leading science and technology company, today announced a collaboration agreement with Iktos, for the use of its generative modelling artificial intelligence (AI) technology, in order to facilitate the rapid and cost-effective discovery and design of promising new compounds.
Three winners of 2019 Sandoz Healthcare Access Challenge (HACk) are announced at SXSW
- Details
- Category: Novartis
Sandoz, a Novartis division, announced the winners of the 2019 Sandoz Healthcare Access Challenge (HACk). Sandoz HACk invites entrepreneurs and innovators in the field of digital technology to submit ideas with the potential to complement - or even positively disrupt - established approaches to driving access to healthcare.
Impact pioneers honored for groundbreaking ideas in the fields of healthcare and nutrition
- Details
- Category: Bayer
The Bayer Cares Foundation recently presented the 2018 Aspirin Social Innovation Awards to five international initiatives for their groundbreaking ideas in the fields of healthcare and nutrition. The award-winners are all impact pioneers whose concepts have the potential to bring about sustainable, systematic changes to thus improve the living conditions of hundreds of millions of people worldwide.
More Pharma News ...
- Ozempic® superior in lowering blood sugar and weight vs placebo, both in combination with SGLT-2 inhibitors
- Novartis data confirm rapid response and high efficacy of Cosentyx® in psoriasis patients for first time in China
- Bayer Thrombosis Research Award 2019 goes to Dr. Changjun Yin
- Jury upholds Amgen's patents on Repatha® (evolocumab)
- Roche enters into definitive merger agreement to acquire Spark Therapeutics
- Brilinta’s Phase III THEMIS trial met primary endpoint in patients with established coronary artery disease and type-2 diabetes
- Amgen, Cytokinetics and Servier announce start of METEORIC-HF, the second Phase 3 clinical trial of omecamtiv mecarbil in patients with heart failure